AI Pharmacovigilance Workflows: Validated, Auditable, Explainable, and Secure

The Pharmacovigilance Automation Imperative

• Pharmacovigilance: the science of detecting, assessing, understanding, and preventing adverse effects of medicines: generates more data than human reviewers can effectively process. The global volume of Individual Case Safety Reports (ICSRs) submitted to regulatory authorities has grown at 20-30% per year through the 2020s, driven by expanded reporting requirements, increased biologics and cell therapy products, and expanded post-market surveillance mandates. The EMA received over 1.5 million ICSRs in 2024; the FDA's FAERS database processes a comparable volume.

Manual pharmacovigilance processes cannot scale to this volume without proportionally scaling the human workforce, a workforce that requires specialised training, operates in a tightly regulated environment, and where error has potentially fatal consequences. AI-powered pharmacovigilance workflows offer the only viable path to processing this volume with maintained or improved quality.

The challenge is not technical capability. The challenge is building AI pharmacovigilance workflows that are validated, auditable, explainable, and secure to the standards required by FDA, EMA, and ICH. A workflow that produces correct safety signals 98% of the time is not acceptable in pharmacovigilance unless you can prove when and why the 2% of errors occurred, demonstrate that those errors were caught by your quality system, and provide a complete audit trail that a regulatory inspector can review.

Regulatory Framework: What Applies

FDA 21 CFR Part 11

Part 11 governs electronic records and electronic signatures in FDA-regulated industries. Its requirements apply to all records that FDA regulations require to be maintained or submitted. Pharmacovigilance records, adverse event case records, workflow processing logs, case assessments, and regulatory submissions, fall within scope.

Key Part 11 requirements for pharmacovigilance AI workflows:

• Audit trails: Automated, computer-generated time-stamped records of operator actions, system-generated events, and data changes. The audit trail must capture: who did what, when, to what record, and what the previous value was. Audit trail records cannot be deleted or modified by system operators.

• Access controls: Operational controls limiting system access to authorised individuals, with user ID and password authentication (or stronger). Shared accounts are non-compliant. Each user must have a unique, traceable identifier.

• Electronic signatures: Where records require signature (case closures, quality reviews, submission certifications), electronic signatures must meet Part 11 requirements: unique to one individual, non-transferable, linked to the signed record.

• Validation: Systems must be validated to demonstrate they consistently produce records that accurately reflect the underlying activities. Validation documentation must be maintained and updated when the system changes.

• Data integrity: Records must be complete, consistent, accurate, and attributable. Data cannot be modified without a linked audit record capturing the change.

EMA Annex 11 and GVP Module VI

EMA's Annex 11 to GMP guidelines applies to computerised systems in GMP-regulated manufacturing and extends to pharmacovigilance operations. GVP (Good Pharmacovigilance Practice) Module VI covers management and reporting of adverse reactions.

EMA's expectations specifically for AI systems used in pharmacovigilance (EMA/INS/GMP/561 and related guidance) include:

• Algorithm validation: AI algorithms used in pharmacovigilance must be validated for their intended use. Validation includes demonstrating the algorithm's performance on representative test sets, documenting known limitations, and establishing acceptance criteria.

• Change control: Any change to the AI model (retraining, hyperparameter adjustment, model version update) must go through a formal change control process, including impact assessment and re-validation if the change is significant.

• Human oversight: AI-generated case assessments must be reviewed by qualified persons before regulatory action. AI can automate triage, prioritisation, and initial assessment, but qualified pharmacovigilance personnel must retain responsibility for final assessments and regulatory submissions.

• Transparency: The basis for AI-generated assessments must be explainable to regulatory inspectors on request. Black-box AI producing outputs without traceable reasoning is not acceptable in regulated pharmacovigilance.

ICH E2B(R3) and HL7 ICSR Data Standards

Individual Case Safety Reports must conform to ICH E2B(R3) data standards for electronic submission. AI workflows processing ICSRs must handle all E2B(R3) data elements correctly, including: patient demographics, drug information (substance, dose, route, indication), adverse event terms (MedDRA coding), seriousness criteria, and outcome information.

MedDRA (Medical Dictionary for Regulatory Activities) coding is a specific technical requirement: adverse event terms must be coded to the current MedDRA version using the appropriate Level of Term (Lowest Level Term, Preferred Term, High Level Term). AI-assisted MedDRA coding must produce terms that a qualified Medical Reviewer would confirm as appropriate, and the AI's term selection must be traceable and correctable.

Architecture of a Validated AI Pharmacovigilance Workflow

Case Ingestion Layer

Adverse event reports arrive through multiple channels: spontaneous reports from healthcare professionals and consumers, literature surveillance, clinical trial data, regulatory authority databases (FAERS, EudraVigilance), social media and digital health data, and partner company reports.

The ingestion layer standardises all inputs to a common case record format before any AI processing:

• Channel-specific parsers: Each source has a defined parser: E2B(R3) XML for regulatory submissions, structured extraction for web forms, NLP extraction for unstructured emails and faxes. All parsers produce the same structured case record schema.

• Receipt acknowledgment and tracking: Every case received is assigned a unique system case number, timestamped, and logged in the case management database. Receipt acknowledgment is sent to the reporter. This tracking is the baseline for regulatory timeline compliance (EU: 15 calendar days for serious unexpected suspected adverse reactions, 90 days for non-serious).

• Duplicate detection: Before any new case enters the workflow, it is compared to existing cases in the database to identify potential duplicates. Duplicate detection uses fuzzy matching on: patient demographics (year of birth, sex, weight), suspect drug, event term, event date, and reporter identity. Suspected duplicates are flagged for human review rather than automatically merged.

AI Case Processing Layer

The AI processing layer handles the high-volume tasks that human reviewers cannot perform at scale:

• Unstructured text extraction: Clinical free-text in adverse event reports contains critical information not captured in structured fields. Claude AI extracts: suspect and concomitant drug names, doses and routes, adverse event terms, temporal relationships (event onset relative to drug start), dechallenge and rechallenge information, and relevant medical history.

n8n workflow for unstructured text extraction: 1. Receive case record with unstructured narrative field 2. Send to Claude API with pharmacovigilance extraction prompt 3. Parse structured JSON response 4. Map extracted terms to case record fields 5. Calculate confidence score for each extracted element 6. Flag low-confidence extractions for human review 7. Write extraction results and confidence scores to case database

• MedDRA coding: Adverse event terms in free text must be mapped to standard MedDRA codes. The AI workflow:

• Seriousness assessment: Determine whether the case meets regulatory seriousness criteria (death, life-threatening, hospitalisation, disability, congenital anomaly, medically significant). AI performs initial seriousness flagging with structured reasoning about which criteria apply.

• Causality assessment: Apply standard causality algorithms (WHO-Uppsala Monitoring Centre criteria, Naranjo scale) based on the extracted case information. The AI calculates algorithm scores and presents the reasoning for each element of the algorithm.

• Signal detection: Identify whether the adverse event-drug combination meets statistical signal detection thresholds (Proportional Reporting Ratio, Reporting Odds Ratio, Bayesian methods). n8n queries the case database with statistical calculation nodes and flags cases meeting signal thresholds for Signal Management review.

Explainability Architecture

Every AI-generated output in the pharmacovigilance workflow must be accompanied by a human-readable explanation of the reasoning. This is both a regulatory requirement (transparency to inspectors) and a quality requirement (reviewers need to understand the basis for AI assessments to review them meaningfully).

• Claude AI explainability design: Each AI prompt in the pharmacovigilance workflow is structured to produce both the output (proposed MedDRA code, causality assessment, seriousness determination) and a structured reasoning narrative. The prompt explicitly requests: "For each conclusion, provide the specific text from the case narrative that supports it, identify any relevant regulatory criteria or pharmacological principles applied, and note any uncertainties or missing information that affect confidence."

• Explanation storage: Explanations are stored linked to the specific AI output version in the case database. They are not overwritten when a human reviewer corrects an AI output: the original AI explanation plus the reviewer's correction and rationale are both preserved. This enables retrospective analysis of AI performance and supports audit trail requirements.

• Reviewable reasoning chains: For complex assessments, the AI produces a step-by-step reasoning chain that a Medical Reviewer can follow and validate. If the AI concludes that a case is causally related, the reasoning chain shows: the temporal relationship calculation, the dechallenge/rechallenge evidence, the known pharmacological mechanism, the existing literature, and the alternative explanations considered.

Human Review Integration

AI outputs are not submitted to regulatory authorities or used for safety decisions without qualified human review. The workflow integrates human review at defined checkpoints:

• Triage review: Medical Reviewer confirms or corrects the AI seriousness determination and validates the case priority assignment (determines which cases are reviewed first based on regulatory timelines and safety significance).

• Medical review: Qualified physician or pharmacist reviews the complete AI-generated case assessment: MedDRA coding, causality assessment, narrative summary: and approves, corrects, or rejects each element with a documented rationale.

• Signal management review: The Signal Manager reviews flagged signal-level findings, confirms or rejects the signal, and determines regulatory communication requirements.

• Quality review: QA reviewer audits a defined percentage of cases (typically 5-10% for established workflows, higher during validation) to verify AI performance and human reviewer compliance with procedures.

Audit Trail Implementation

The audit trail for pharmacovigilance AI workflows requires several layers beyond standard system audit logs:

• Case-level audit trail: Immutable record of every change to every field in every case record. Format: case_number, field_name, old_value, new_value, changed_by (user ID or system process ID), timestamp, change_reason.

• AI output audit trail: Record of every AI output including: the exact prompt used, the model version, the input data hash, the full AI output (not just the accepted portions), and the confidence scores. Stored in a separate AI outputs table linked to the case record.

• Review audit trail: Record of every human review action: reviewer ID, case number, AI output ID reviewed, review action (approved / corrected / rejected), correction made, rationale for correction, and timestamp.

• System event audit trail: System-level events: workflow execution starts and completions, API call logs (to Claude, to MedDRA lookup services, to regulatory submission systems), authentication events, and system configuration changes.

All audit trail tables are append-only (enforced at database level via triggers that prevent UPDATE and DELETE operations). Database-level audit logs capture any attempt to bypass application-level controls.

Validation Documentation for AI Pharmacovigilance Systems

GAMP 5 (Good Automated Manufacturing Practice) provides the validation methodology framework. AI pharmacovigilance systems are typically classified as GAMP Category 5 (custom software), requiring full validation documentation:

• User Requirements Specification (URS): Define what the system must do from the user perspective. Includes: functional requirements (case ingestion, AI processing, human review workflow), performance requirements (processing time, throughput), and regulatory requirements (audit trail, Part 11 compliance).

• Functional Requirements Specification (FRS): Translate URS into specific system functions. Each function traces to one or more URS requirements.

• Software Design Specification (SDS): Document the technical architecture. For AI components: model selection rationale, training data description, acceptance criteria for model performance, and update/retraining procedures.

• Installation Qualification (IQ): Document that the system is installed correctly: server configuration, software versions, network configuration, security settings. Execute and record IQ tests.

• Operational Qualification (OQ): Test that each system function works as specified against the FRS. For AI components: test against a defined dataset with known correct outputs, calculate performance metrics (sensitivity, specificity, positive predictive value for key functions like seriousness determination), and compare to acceptance criteria.

• Performance Qualification (PQ): Test that the complete integrated system performs correctly under production conditions. Include peak volume testing, edge case testing, and error handling testing.

• AI Algorithm Validation Report: Specific to AI components, document: training dataset characteristics (size, source, date range, MedDRA version), model architecture, training methodology, validation dataset performance metrics, known limitations and failure modes, and monitoring plan for ongoing performance.

Security Architecture

Pharmacovigilance data contains patient health information. Under HIPAA (US), GDPR (EU), and equivalent national laws, it requires appropriate security measures:

• Access control: Role-based access with minimum privilege. Data entry personnel access only case input functions. Medical reviewers access only their assigned cases plus completed cases for quality reference. Administrators access system configuration but not case data. All access uses unique individual credentials with MFA.

• Data encryption: Cases encrypted at rest (AES-256) and in transit (TLS 1.3). AI API calls to Claude include only the minimum data necessary for the specific processing task: narrative text for extraction, not the full case record with all identifiers.

• Network security: Pharmacovigilance systems operate on isolated network segments with firewall controls limiting external connectivity to defined endpoints (regulatory submission systems, Claude API, MedDRA lookup services). All external calls are proxied and logged.

• Penetration testing: Annual penetration testing by a qualified third party. Findings tracked through to remediation with documented timelines.

• Incident response: A documented incident response plan covering: data breach detection, containment procedures, regulatory notification timelines (GDPR 72-hour notification requirement), and post-incident review.

n8n + Claude Implementation Specifics

n8n serves as the orchestration layer connecting all components of the pharmacovigilance workflow. Claude AI handles the NLP-intensive steps: unstructured text extraction, causality reasoning, and narrative generation.

n8n configuration for Part 11 compliance

• All workflow executions logged to the audit database via n8n's built-in execution log plus custom logging nodes
• Workflow changes managed through version control (Git) with documented change approval
• Production workflows locked after validation: changes require a new release through the change control process
• Error handling workflows that prevent cases from entering invalid states on failure

Claude API integration specifics

• Use Claude Sonnet (claude-sonnet-4-20250514) for complex extraction and reasoning tasks requiring high accuracy
• Use Claude Haiku for high-volume, lower-complexity classification tasks to manage cost
• All Claude API calls include the pharmacovigilance system prompt that constrains Claude's responses to the specific extraction schema
• API responses are validated against the expected JSON schema before being written to the case database
• Failed validations are logged and routed to manual review rather than allowing malformed data into the case record

Frequently Asked Questions

Does using AI in pharmacovigilance require regulatory notification or approval?

Generally, no pre-approval is required to use AI tools in pharmacovigilance operations, but the computerised system must be validated and the MAH (Marketing Authorisation Holder) retains responsibility for the quality of pharmacovigilance outputs regardless of AI involvement. Some national competent authorities are developing specific AI guidance, monitor relevant regulatory agency communications.

How do we handle AI model updates in a validated system?

Through a formal change control process. When a model update is available (new Claude version, retrained internal model), submit a change request documenting: the nature of the change, the potential impact on validated functions, the proposed re-validation scope, and the implementation plan. Execute the approved re-validation before deploying the updated model to production.

What is the acceptance criteria for AI performance in MedDRA coding?

Typical acceptance criteria for AI-assisted MedDRA coding: Preferred Term agreement between AI and qualified Medical Reviewer ≥85% for spontaneous reports, ≥90% for structured literature data. All disagreements investigated in validation OQ phase and categorised (AI correct, reviewer correct, both acceptable alternatives). Final criteria documented in the validation plan and subject to regulatory inspector review.

Can Claude AI be used in a Part 11 compliant workflow given it is a third-party cloud service?

Yes, with appropriate controls. Claude API is called with de-identified or pseudonymised data (patient identifiers replaced before API call), under a Data Processing Agreement with Anthropic, with TLS encryption for all communications, and with all inputs and outputs logged for audit trail. The validation documentation addresses the third-party AI component specifically, including how its outputs are validated and how model version changes are managed.

What staff qualifications are required for AI pharmacovigilance workflows?

AI-assisted pharmacovigilance does not reduce the qualification requirements for human reviewers, Medical Reviewers must still be medically qualified pharmacovigilance professionals. Additional competencies required for AI workflow oversight: understanding of AI system limitations and failure modes, ability to critically evaluate AI outputs rather than passively accept them, and familiarity with the validation and change control requirements for AI systems.

How should we handle AI disagreement with an experienced reviewer's assessment?

The reviewer's assessment governs, AI does not override qualified human judgment. The disagreement is documented in the audit trail with both the AI assessment and the reviewer's assessment and rationale. Systematic AI-reviewer disagreements are analysed in periodic performance reviews to identify whether they reflect AI performance issues, reviewer inconsistencies, or complex cases requiring guideline clarification.

PURIST builds validated, GxP-compliant workflow automation systems for pharmaceutical and biotech companies. Contact us to discuss your pharmacovigilance automation requirements and the validation documentation package we provide with each deployment.